A Comparitive Study of Over Instruction Recommended Usage Artesunate Injection on Severe Malaria Patients and Instruction Recommended Usage Artesunate Injection on Severe Malaria Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17013106

Enrollment

Unknown

Registered

2017-10-25

Start date

2009-12-01

Completion date

Unknown

Last updated

2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Interventions

All people:Artesunate

Eligibility

Sex/Gender

All

Age

25 Years to 69 Years

Inclusion criteria

Inclusion criteria: All patients diagnosed as severe malaria (inclueding coma and pre-coma patients)

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

Measure	Time frame
Glasgow Coma Scale;Plasmodium Blood Smear;Body Temperature;	—

Secondary

Measure	Time frame
PCR Analysis for Plasmodium;Blood Pressure;Routine Blood Test;Routine Urine Test;Serum Creatinine;Chest X-Ray;Blood Glucose;Carbon Dioxide Combining Power;Serum Bilirubin;	—

Countries

China

Contacts

Public ContactHuang Yaming

People's Hospital of Shanglin, Guangxi Zhuang Autonomous Region

1724501964@qq.com+86 13517669134

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026